Impact of Neo-Adjuvant Chemotherapy in Triple Negative Breast Cancers

Objective: To evaluate the impact of Neo-Adjuvant Chemotherapy on Pathological Complete Response rates, in patients with Triple-Negative Breast Cancer, focusing on the relationship between tumor size, nodal involvement, type of surgery, and treatment outcomes. Study Design: Prospective cohort study. Place and Duration of Study: Pakistan Navy Station Shifa Hospital, Karachi Pakistan, from Feb 2023 to Feb 2025. Methodology: A total of 88 patients with triple-negative breast cancer who received neoadjuvant chemotherapy were included. Baseline characteristics, including tumor size, nodal involvement, and type of surgery, were recorded. The chi-square test was used to compare pathological complete response rates between subgroups. A p-value of <0.05 was considered statistically significant. Results: The overall Pathological Complete Response rate was 43.18%. Nodal involvement was significantly associated with Pathological Complete Response (p=0.01), with N0 patients achieving higher response rates compared to N1 and N2 patients. Tumor size and type of surgery were not significantly associated with Pathological Complete Response (p=0.13 and p=0.30, respectively). Tumor size and type of surgery did not significantly affect outcomes. Adverse effects were observed in 21.59% of patients, with no significant impact. Conclusion: Neo-Adjuvant Chemotherapy is effective in achieving Pathological Complete Response in Triple-Negative Breast Cancer patients, particularly in those without nodal involvement.